VolitionRx Limited, a multinational epigenetics company, announced results from a clinical study demonstrating high accuracy of its Nu.Q Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, meaning no false positives, the blood-based assay detected more than 80% of feline lymphomas, supporting development of what the company expects to be the world’s first simple and affordable liquid biopsy test for feline cancer.
The company stated that feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging after symptoms have progressed, and noted that veterinarians have sought a feline screening solution for years. Following the international rollout of its canine cancer test, VolitionRx indicated it has now demonstrated the technology’s effectiveness in cats and plans to complete product development and make the Nu.Q Vet Feline Test available through existing distribution networks, including reference laboratories and point-of-care platforms.
This development matters because early cancer detection in companion animals has been limited by diagnostic challenges. Traditional methods often involve invasive procedures that require anesthesia and carry risks, while advanced imaging like CT scans can be prohibitively expensive for many pet owners. A simple blood test could transform veterinary oncology by enabling routine screening during regular check-ups, potentially identifying cancers before clinical symptoms appear.
The implications extend beyond feline health. Successful implementation of this technology in veterinary medicine could validate the underlying epigenetic detection approach for broader applications. VolitionRx is developing similar blood tests for human cancers and other diseases, with research and development activities centered in Belgium and additional facilities in the U.S. and London. The company’s broader mission involves advancing epigenetics to save lives and improve outcomes for both people and animals through earlier detection and monitoring of life-altering diseases.
For further information about the company’s work, visit https://volition.com/. The announcement was distributed through BioMedWire, a specialized communications platform focusing on biotechnology and life sciences developments that is part of the Dynamic Brand Portfolio at IBN. More information about this platform is available at https://www.BioMedWire.com.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VolitionRx Study Shows Blood Test Accurately Detects Lymphoma in Cats.